IGM Biosciences (IGMS)
(Delayed Data from NSDQ)
$9.40 USD
+1.75 (22.88%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $9.41 +0.01 (0.11%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Brokerage Reports
0 items in cart
IGM Biosciences, Inc. [IGMS]
Reports for Purchase
Showing records 61 - 80 ( 84 total )
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
IgM Platform is Impressive but Value Looks Baked In; Downgrading to NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
ASH 2020 Takeaways - First Response Look at IGM-2323 in NHL
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
IGM-2323''s Efficacy Likely to Improve At Higher Doses; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials; Additional IGMS-2323 Data Ahead at ASH
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
IGM-8444 Phase 1 Trial Initiated; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials; ASH Readout Ahead; DR5 Study Set to Initiate
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
A New Dawn in Antibody Therapeutics; Initiating at Buy and $88 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Exploiting Addiction: A Review of Synthetic Lethality in Cancer
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
AACR II 2020 Abstract Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financials; Initial Data for 2323 Remains on Track for YE:20
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R